Melanoma Clinical Trials Intelligence
Monthly Update Report for Trials Started in May 2026
Powered by Sophic Starlight
Sophic does not practice medicine nor provide medical advice. The Sophic Starlight Cancer Clinical Trials Intelligence Report is provided for educational and consulting purposes only. This report is not a substitute for professional medical advice, diagnosis, or treatment. Sophic shall not be held responsible for any interpretation, application, or use of this report beyond these purposes.
The Sophic Starlight Cancer Clinical Trials Intelligence Report is intended solely as an educational resource that provides access to publicly available clinical trial data integrated within Sophic’s proprietary knowledgebase and summarized with AI. Reports are provided entirely free of charge, and patients should never be billed or charged for access to this information. Users agree to reference Sophic in any publication, presentation, or publicity that incorporates or relies upon information from Sophic Starlight Cancer Clinical Trials Intelligence Reports.
1: Summary data from new trials identified for Melanoma.
Overview
Number of Trials: 1
This feasibility study evaluates a methionine-reduced diet in patients with metastatic, recurrent, or unresectable solid tumors, including gliomas. The dietary intervention targets cancer cells' dependence on methionine for proliferation. Patients must be able to receive standard cancer therapy and comply with the prescribed diet.
Common Criteria Across Trials
Common Inclusion
- Age 18 years or older
- Diagnosis of metastatic, recurrent, or unresectable solid tumors
- Life expectancy at least 3 months
- ECOG performance status 0-2
- Adequate organ function
- Negative pregnancy test for women of childbearing potential
- Willing to comply with methionine-reduced diet
- Written informed consent
- Able to receive systemic standard of care cancer therapy
Common Exclusion
- Uncontrolled or symptomatic brain metastases
- Active infections requiring systemic therapy
- Severe cardiovascular conditions
- Uncontrolled diabetes
- Severe liver disease or cirrhosis
- Inherited metabolic disorders affecting amino acid metabolism
- Severe gastrointestinal disorders impairing nutrient absorption
- Major surgery within 4 weeks
- Concurrent malignancies requiring active treatment
- Pregnancy or breastfeeding
- Severe malnutrition
- Substance abuse within past 6 months
- Chronic kidney disease stage 3b or higher
- Psychiatric disorders interfering with consent or adherence
- Allergies or intolerances to low-methionine foods
2: Extracted Trials with New Information
Trials with Special Criteria
Unique or Unusual Criteria
- NCT07628634 — Requires willingness and ability to comply with a methionine-reduced diet; excludes patients with metabolic disorders affecting amino acid metabolism or severe nutrient absorption issues
Trials with Emerging Treatments
- NCT07628634 — Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients With Solid Tumors
Items: Methionine-Reduced Diet
Note: Novel dietary intervention targeting cancer cell dependence on methionine for proliferation; preclinical evidence suggests efficacy in melanoma
3: Individual Trial Overviews
NCT07628634
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients With Solid Tumors
Organization/Sponsor: University of California, Irvine
Example patient: A 55-year-old man with unresectable metastatic melanoma, ECOG performance status 1, adequate organ function, no recent surgeries, and willing to adhere to a methionine-reduced diet while receiving standard systemic therapy.
Phase N/A
NCT07628634
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients With Solid Tumors
Organization/Sponsor: University of California, Irvine
Example patient: A 55-year-old man with unresectable metastatic melanoma, ECOG performance status 1, adequate organ function, no recent surgeries, and willing to adhere to a methionine-reduced diet while receiving standard systemic therapy.
Interventions
-
Dietary Intervention: Methionine-Reduced Diet
Summary: Methionine-reduced diet limits methionine intake to inhibit cancer cell growth by targeting cancer cells' reliance on methionine for proliferation. Preclinical studies suggest effectiveness against melanoma by reducing cancer cell survival. Source: Summary of Web Search.
Key Inclusion
- Age 18 years or older
- Metastatic, recurrent, or unresectable solid tumors
- Life expectancy at least 3 months
- ECOG performance status 0-2
- Adequate organ function
- Willing to comply with methionine-reduced diet
- Able to receive systemic standard of care cancer therapy
- Negative pregnancy test for women of childbearing potential
Key Exclusion
- Uncontrolled or symptomatic brain metastases
- Active infections requiring systemic therapy
- Recent myocardial infarction within 6 months or uncontrolled cardiovascular conditions
- Severe liver disease or inherited metabolic disorders affecting amino acid metabolism
- Major surgery within 4 weeks
- Pregnant or breastfeeding
- Severe malnutrition or significant nutritional deficiencies
- Chronic kidney disease stage 3b or higher